Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00002852
Other study ID # NCI-2012-02967
Secondary ID CALGB-9633CDR000
Status Completed
Phase Phase 3
First received November 1, 1999
Last updated July 2, 2013
Start date October 1996

Study information

Verified date July 2013
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Randomized phase III trial to compare the effectiveness of surgery with or without combination chemotherapy in treating patients who have stage I non-small cell lung cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether surgery is more effective with or without chemotherapy for non-small cell lung cancer.


Description:

PRIMARY OBJECTIVES:

I. To determine if adjuvant chemotherapy can favorably alter the prognosis of the subgroup of resected stage I patients who, following complete surgical resection of their disease, are defined as "high risk" based on the presence of a T2N0 tumor (according to the criteria of the International Staging System for lung cancer).

SECONDARY OBJECTIVES:

I To compare failure-free survival of patients with T2N0 stage I NSCLC who have and have not been treated with adjuvant chemotherapy.

II. To determine the toxicities associated with adjuvant chemotherapy. III. To describe the pattern of disease recurrence.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to tumor histology (squamous cell vs nonsquamous cell), degree of differentiation (poorly differentiated vs other), and mediastinal node sampling at surgery (yes vs no). Within 4-8 weeks after surgery, patients are randomized to 1 of 2 treatment arms.

Arm I:Patients receive no further therapy.

Arm II: Patients receive adjuvant therapy comprising paclitaxel IV over 3 hours followed by carboplatin IV over 1-2 hours on day 1. Treatment continues every 3 weeks for 4 courses.

Patients are followed every 4 months for 2 years and then every 6 months thereafter.


Recruitment information / eligibility

Status Completed
Enrollment 500
Est. completion date
Est. primary completion date July 2004
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically documented non-small cell carcinoma

- Completely resected T2N0M0 Stage I NSCLC as defined by the International Staging System

- Surgery shall consist of a lobectomy or pneumonectomy with resection of associated N1 lymph nodes (either by thoracotomy or thoracoscopy)

- Patients must be randomized within 4 to 8 weeks from the date of complete surgical resection

- No prior chemotherapy or radiation for non-small cell lung cancer

- Performance status of 0 or 1

- Women must be non-pregnant and non-lactating; patients of childbearing potential must agree to use an effective form of contraception while on study

- Patients must have no history of previous or concomitant malignancy, other than curatively treated carcinoma in situ of the cervix, or basal cell or squamous cell carcinoma of the skin, or surgically treated in situ carcinoma of the breast, or other cancer for which the patient has bee disease free for five years

- Granulocytes >= 1,800/ul

- Platelets >= 100,000/ul

- Bilirubin < 1.5 mg/dl

- SGOT (AST) < 2.0 x ULN

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Intervention

Drug:
paclitaxel
Given IV
carboplatin
Given IV
Procedure:
therapeutic conventional surgery
Undergo surgery

Locations

Country Name City State
United States Cancer and Leukemia Group B Chicago Illinois

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall survival (OS) OS curves will be calculated using the Kaplan-Meier life-table method. Comparison of the survival curve for the two treatment regimens will be performed using the log-rank test for censored data. Up to 2.4 years No
Primary Failure-free survival Failure-free survival curves will be calculated using the Kaplan-Meier life-table method. Time between randomization and disease relapse or death, assessed up to 2.4 years No
Secondary Toxicity as assessed by Common Toxicity Criteria version 2.0 Up to 1 year after completion of treatment Yes
Secondary Pattern of disease recurrence. The frequency of local and distant relapse and the incidence of a second primary lung cancer will be tabulated by treatment. Up to 2 years No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03177291 - Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC Phase 1
Withdrawn NCT03346304 - Photodynamic Therapy for the Prevention of Lung Cancer Phase 2/Phase 3
Recruiting NCT02288026 - Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung Cancer N/A
Terminated NCT01491633 - Dasatinib in Advanced Squamous Cell Lung Cancer Phase 2
Completed NCT00087412 - S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer Phase 2
Completed NCT00049543 - Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery Phase 3
Active, not recruiting NCT04357873 - Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations Phase 2
Recruiting NCT02787473 - A Study of Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Docetaxel Consolidation in Patients With Inoperable Squamous Cell Lung Cancer Phase 2
Completed NCT00387374 - Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab Phase 2
Recruiting NCT05550961 - APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch
Active, not recruiting NCT05292859 - Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs
Recruiting NCT05607108 - A Study of ZEN003694 in People With Squamous Cell Lung Cancer Phase 2
Terminated NCT03574818 - Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable - 14X-US-I001 Phase 2
Suspended NCT00909558 - Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer Phase 1
Completed NCT00040794 - Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer Phase 2
Terminated NCT00042835 - Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer Phase 1
Terminated NCT03827850 - FGFR Inhibitor in FGFR Dysregulated Cancer Phase 2
Active, not recruiting NCT01345851 - Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery N/A
Withdrawn NCT02059967 - Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC Phase 1
Completed NCT01082549 - Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC) Phase 3